Dr. Batycky has over two decades of experience with biotech start-ups from founding to acquisition across an array of platforms and disease states with significant expertise in inhaled drug development. Most recently, he was the Chief Scientific Officer and a founder of Civitas Therapeutics, which was acquired by Acorda. At Acorda, he was Chief Technology Officer where he led its novel dry powder inhalation therapy to treat motor issues in Parkinson's patients through to FDA approval as Inbrija™. Prior to that he was Chief Scientific Officer and Senior VP of R&D at Pulmatrix and held prior positions at Alkermes and Advanced Inhalation Research. Dr. Batycky received his B.Sc. in Chemical Engineering from the University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).